Abuse of anabolic androgenic steroids (AAS) and opioids intersects in athletics. Evidence from humans and animals suggests that AAS may act in the brain through opioidergic mechanisms, and may potentiate effects of opioids.
Introduction
Although anabolic androgenic steroids (AAS) are controlled substances, AAS users downplay similarities with street drugs, arguing that 'unlike, say, crack addicts, the men who take steroids are basically healthy, clean-living people' [1] . However, emerging evidence suggests that AAS users may abuse other drugs, particularly opioids [2] [3] [4] [5] [6] . Kashkin and Kleber [7] hypothesized that AAS dependence might involve opioidergic mechanisms. Arvary and Pope [2] suggested that AAS could act as a gateway drug to opioid dependence. Among 223 men entering drug treatment, AAS use was considerably higher (25%) among opioid users, compared with men using other drugs (5%) [3] . A recent study from New Zealand found that 50% of dependent AAS users also meet Diagnostic and Statistical Manual of Mental Disorders, 4th ed. criteria for a lifetime history of opioid abuse or dependence, compared with 19% of nondependent AAS users and 7% of nonusers [8] . In the clinical literature, naloxone has been used to treat AAS withdrawal in bodybuilders [4] , and AAS appear to interact with heroin in accidental drug overdose [5] .
Animal studies also support links between AAS and opioids. At physiologic levels, testosterone enhances the response to opioids [9] . At pharmacologic levels, testosterone selfadministration intracerebroventricularly causes autonomic depression similar to opioid overdose, which is blocked by the opioid antagonist naltrexone [10] . In other studies, AAS have been found to enhance morphine-induced hypothermia [11] , although they reduce analgesic effects of morphine [12] and attenuate tolerance to morphine's antinociceptive action [11] . This is consistent with AAS-induced opioid receptor binding in the brain [13] .
The present study sought to determine whether AAS increase motivation for morphine. The approach was to compare operant responding for morphine under both fixed-ratio (FR) and progressive-ratio (PR) schedules of reinforcement in morphine-dependent male rats exposed chronically to highdose testosterone or vehicle. PR reinforcement estimates relative reinforcing efficacy, in which the animal is required to make increasing numbers of responses for each successive reinforcement [14] . If testosterone enhances motivation for morphine, testosterone-treated males should complete more ratios than vehicle-treated males. We also determined whether testosterone enhances the sedative effects of morphine on locomotor activity. housed under a reversed 14 light : 10 dark photoperiod (lights off at 9 a.m.) and stable ambient temperature (241C). This long-day photoperiod is equivalent to summer day lengths in Los Angeles. Food and water were available ad libitum, except during training for food reward. Rats remained gonad-intact to approximate AAS use in humans. Care was provided by the University of Southern California (USC) vivarium. Experimental procedures were approved by the Institutional Animal Care and Use Committee of USC and were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals, 8th ed. (National Research Council, National Academies Press, Washington, DC, USA; 2011).
Anabolic androgenic steroid treatment
Beginning at 7 weeks of age, rats received testosterone (7.5 mg/kg; Steraloids Inc., Newport, Rhode Island, USA) or vehicle [3% ethanol, 13% cyclodextrin (RBI, Natick, Massachusetts, USA) in water] by daily subcutaneous injection (n = 8/group). Compared with oil, the aqueous vehicle improves steroid bioavailability. This approximates a dose of 450 mg/week in humans adjusted to body surface area according to US Federal Drug Administration guidelines, and has been used to demonstrate effects of AAS on behavior in rats [15, 16] .
Morphine self-administration Operant chambers
Training and testing were conducted in operant chambers (Med Associates, St. Albans, Vermont, USA) connected to a personal computer running WMPC software (Med Associates). Each chamber was equipped with a house light, a computer-controlled syringe pump connected through the lever arm with fluid swivel, a food pellet dispenser, and two levers, each with stimulus light.
Behavior was tested during the start of the dark phase, with the house light illuminated. Initially, rats were trained to respond for 45-mg sucrose pellets (Bioserv, Frenchtown, New Jersey, USA) under an FR2 schedule in daily 20-min sessions. A stimulus light facilitated responding on the correct lever. During training, rats were maintained on a slow rate of growth (1-2 g/day). Once rats achieved 50 pellets/session, food was available ad libitum, and each rat was implanted with a chronic Silastic jugular catheter (Dow Corning, Midland, Michigan, USA), connected to a 22 G cannula assembly on the dorsal skin. Catheters were flushed daily with 25 IU/ml heparin and 0.125 mg/ml gentamicin sulfate in saline.
The study followed established methods for morphine dependence and self-administration under FR and PR schedules [14] . Initially, rats received continuous morphine infusion for 7 days. The dose was increased by 20% each day from 16.8 to 50.0 mg/kg/day. Next, rats were tested 6h/day for 3 days for self-administration of 3.2mg/kg morphine on an FR1 schedule, in which each response on the lever delivered a morphine infusion. A noncontingent injection was delivered at the start of each session, and rats were limited to 44 injections/session. During FR and PR sessions, the stimulus light over the active lever was illuminated, and only responses on the active lever were reinforced. When the active lever was pressed (FR) or a ratio was completed (PR), morphine was delivered through a syringe pump, and both the stimulus and house lights were extinguished for 5 s. Responses on the active lever during this time-out were recorded, but not reinforced.
Once rats received more than 20 morphine infusions for two consecutive FR1 sessions, they were tested on a PR 9-4 schedule for 1 week. For PR, the response requirement is initially one response per morphine infusion, but increases with successive infusions. The breakpoint, when the rat ceases to respond, provides an estimate of relative reinforcing efficacy. Under the PR 9-4 schedule ( Fig. 1 ), the rat must complete nine ratios before the response requirement is equal to four lever presses. Compared with PR schedules for cocaine self-administration (e.g. PR 3-4), the PR 9-4 schedule supports operant responding for morphine [14] . Responses on the 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20   1  1  1  2  2  2  3  3  4  4  5  5  6  6  7  7  8  9  9  10 Step Response requirement active lever during time-out were not counted toward the next ratio.
Morphine intoxication
To determine whether chronic high-dose testosterone administration increases the sedative effects of morphine, separate groups of rats were treated for at least 6 weeks with testosterone or vehicle, as described above. Daily injection of testosterone or vehicle continued throughout open-field testing. These male rats were videotaped for 30 min in an open field (0.8 Â 0.8 m, grid lines every 20 cm) following daily treatment (testosterone or vehicle) and injection of saline intraperitoneally. Videotaping was repeated 1 week later after daily treatment followed by injection of 10 mg/kg morphine intraperitoneally. Videos were analyzed for line crossing and rearing by an observer blinded to treatment groups.
Statistical analysis
Morphine intake and operant responses on both levers during FR1 and during the final three sessions of PR were averaged for each rat. Group means from testosteronetreated and vehicle-treated male rats were compared using Student's t-test. Locomotor responses to saline and morphine in vehicle-treated and testosterone-treated rats across the 30-min test were analyzed using repeatedmeasures analysis of variance. Statistical significance was set at P less than 0.05.
Results
Vehicle-treated and testosterone-treated rats required the same amount of time to meet the criteria for FR2 food training (NS; Fig. 1 ). Body weight also did not differ significantly between the two groups. Under FR1, morphine intake was substantially greater, compared with that under the PR 9-4 schedule of reinforcement. Whereas vehicle-treated and testosterone-treated male rats consumed similar amounts of morphine under the PR schedule (NS), self-administration under FR1 was significantly lower in testosterone-treated rats (63.2±7.2 mg/kg/day) compared with vehicle-treated controls (95.9±8.5 mg/kg/day; P < 0.05).
Under an FR1 schedule, vehicle-treated rats responded more vigorously to 3.2 mg/kg morphine, averaging 30.0±2.7 responses/6 h versus 19.7±2.3 responses in testosterone-treated rats ( Fig. 2 ; P < 0.05). The number of unreinforced responses on the active lever did not differ between the two groups (NS), nor did the number of responses on the inactive lever (NS).
Under a PR 9-4 schedule of reinforcement, there was no effect of testosterone on responding for 3.2 mg/kg morphine, as shown in Fig. 3 . On average, vehicle-treated rats completed 10.6±1.2 ratios in 6 h (range 6.0-15.0), with a maximum requirement of 5.0±0.6 responses to receive a morphine infusion (30.9±5.9 responses/6 h). This is comparable with the findings from previous studies [14] . Testosterone-treated rats completed 9.6±1.1 ratios/6 h (range 5.5-13.0), for a maximum response requirement of 4.6±0.6 responses (26.7±5.7 responses/6 h; NS). Both groups of rats made few unreinforced responses on the active lever, but responded vigorously on the inactive lever (NS).
When tested for locomotor activity (Fig. 4) , there was a significant effect of time [F (3, 18) = 13.845, P < 0.05] by repeated-measures analysis of variance. Rats showed high levels of exploratory behavior initially, which declined throughout both 30-min tests. This decrease in locomotor activity was especially marked after administration of 
Discussion
The present study chronically exposed male rats to high levels of testosterone and tested them for morphine selfadministration to determine whether AAS increase the rewarding effects of opioids. Rats received noncontingent morphine infusions and were tested under FR1 and PR schedules of reinforcement. Under the FR1 schedule, a single lever press delivered an infusion of morphine intravenously. To measure motivation for morphine, the PR schedule increased the responses for each infusion. Testosterone failed to increase morphine intake. Indeed, during FR1 self-administration, testosterone-treated rats consumed less morphine than did vehicle-treated controls. This suggested the possibility that AAS might enhance the sedative effects of opioids. Accordingly, we compared locomotor activity and rearing in separate groups of testosterone-treated and vehicle-treated rats in response to saline or morphine. Morphine suppressed both rearing and locomotion. Testosterone selectively decreased rearing without altering locomotor activity. Although previous studies in animals and humans have demonstrated interactions of AAS with opioids, in terms of both behavior and neurochemistry [13] , it appears that testosterone does not substantially increase motivation for morphine self-administration.
The incidence of nonmedical use of AAS or opioids in the USA is surprisingly high. According to the 2012 Monitoring the Future survey, 12.2% of American 12th grade students have engaged in nonmedical use of opiates (narcotics other than heroin), and 1.8% have used AAS [17] . Moreover, it is likely that these data underestimate the prevalence of AAS use, as most users start in their early 20's [3] . Surveys of opioid users in treatment show relatively high rates of concurrent AAS use [2] . As posited by Arvary and Pope [2] , AAS may serve as a gateway drug for opioids. The present study was designed to address this question in animals. Animal studies can examine the reinforcing effects of AAS unencumbered by the motivation to increase muscle mass and athletic performance. The present study used testosterone and morphine because these are the prototypic steroid and narcotic, respectively. All AAS are derived from testosterone, have a similar 19-carbon structure, and bind to the androgen receptor (AR). Morphine is the most abundant opiate from the opium poppy. It is a potent analgesic in clinical use, but also has potential for abuse. Rewarding and analgesic effects are mediated through the m-opioid receptor (MOR). Reinforcing effects of morphine are mediated through the ventral tegmental area (VTA) and nucleus accumbens (Acb), whereas negative aspects of morphine withdrawal involve actions in the bed nucleus of the stria terminalis (BST), periaqueductal gray (PAG), and preoptic area (POA) [18] . Although VTA and Acb have relatively few AR-positive neurons, AR are abundant in BST, PAG and POA [16] . These brain areas may represent neuroanatomical substrates for interaction of AAS and opioids.
Animal studies have already suggested the potential for interactions of AAS with opioidergic systems involving MOR and its ligands. When male hamsters self-administer testosterone intracerebroventricularly, they show symptoms reminiscent of opioid overdose: hypothermia, low respiration, and locomotor activity [10] . These can be reversed by administration of the preferential MOR antagonist naloxone, and naloxone pretreatment blocks testosterone self-administration. Interactions of AAS and opioids are also evident when they are administered together: nandrolone reduces morphine-induced conditioned place preference in mice, and potentiates symptoms of naloxone-induced morphine withdrawal [11] . On that basis of the observations from humans and animal studies, we hypothesized that testosterone might increase operant responding for intravenous morphine self-administration.
However, using an established PR regime for morphine self-administration [14] , the present study did not find evidence of greater reinforcing efficacy in male rats chronically exposed to high-dose testosterone. Although these findings did not support our hypothesis, they are consistent with subjective reports from human users. Many athletes use AAS and opioids for their anabolic and analgesic effects, respectively. Intoxication and euphoria are not primary objectives [8] . Therefore, synergistic effects on reward and reinforcement are not necessarily essential for coabuse of AAS and opioids in humans. In view of the presence of AR in brain regions that contribute to aversive aspects of morphine withdrawal (e.g. BST, PAG, and POA), it is tempting to speculate that AAS may modify symptoms of opioid withdrawal. This remains to be tested.
Of course, AAS and opioids may interact in the brain to modify other behavioral responses. Human users believe that AAS reduce pain and ensure speedy recovery from overtraining injury. Studies in rats and mice have found no antinociceptive effect of AAS on acute thermal or inflammatory pain [19] . Instead, steroids appear to modify the response to opioids: they reduce morphine-induced analgesia [12] and attenuate tolerance to antinociceptive effects of morphine [11] . In a similar manner, nandrolone increases the hypothermic effects of morphine in mice [11] . These findings are consistent with those of a study on AAS use in deaths from heroin overdose. Coabuse of AAS appears to reduce the lethal threshold for heroin overdose [5] , in which case death is due to hypothermia and respiratory depression. There is also potential for AAS to enhance the sedative effects of opioids, including suppression of locomotor responses [11, 20] . Increased sedation is consistent with the lower intake of morphine on an FR1 schedule of reinforcement in testosterone-treated rats from the present study. Interactions of AAS and opiates to reduce activity might seem surprising, as AAS are used most often in conjunction with intensive exercise. By itself, testosterone has minimal effects on locomotor activity [11] . The present study reported similar results for open-field locomotion. However, testosterone decreased rearing behavior compared with vehicle. Rearing may represent exploratory behavior [20] , but may also reflect anxiety [21] , and is a symptom of opioid withdrawal in rodents [22] .
A number of studies have investigated neurobiologic interactions of AAS and brain opioid systems [13] . AAS reduce MOR in cultured neuroblastoma cells [23] . In the brain, AAS modify endogenous opioids and opioid receptors in a region-specific manner. AAS reduce b-endorphins in Acb [13] and the hypothalamic arcuate nucleus [24] . b-Endorphins are increased by AAS in the paraventricular thalamus [25] and hypothalamus, BST [24] , and VTA [13] . Further, intracerebroventricular infusion of testosterone acutely stimulates Fos in VTA [16] , even as systemic AAS reduce Fos response to morphine in the caudate putamen [25] . Together, these results suggest that AAS may modify the activity of the b-endorphin/MOR system through a combination of classical AR-mediated mechanisms, as well as through nongenomic actions. Further studies on modification of MOR by AAS will help reveal the mechanisms of action of AAS in the brain.
